Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether fenofibrate effects the toleration, safety, or efficacy biomarkers of CP-742,033, a drug being developed for the treatment of obesity.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pfizer
• Treatments: Fenofibrate

Criteria

Inclusion Criteria:

• BMI of 30-40 kg/m2

Exclusion Criteria:

• Women of childbearing potential